Labiotech.eu

News and Trends 19 Jul 2023

Moleculin issues acute myeloid leukemia drug data

Moleculin Biotech, Inc., a clinical stage pharmaceutical company with drug candidates targeting hard-to-treat tumors and viruses, has published data from its completed MB-105 European phase 1 clinical trial assessing the safety and efficacy of annamycin as a single agent for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML). ‘Results of a […]

July 19, 2023 - 3 minutesmins - By Jim Cornall

Ziwig revolutionizes endometriosis diagnosis

In Depth 18 Jul 2023

Ten years to ten days: French startup revolutionizes early diagnosis of endometriosis with a saliva test

A condition that affects around 190 million women and girls worldwide, according to the World Health Organization, endometriosis is a chronic, difficult-to-treat disease that causes debilitating pelvic pain. Often misdiagnosed as irritable bowel syndrome (IBS) and sometimes dismissed as menstrual cramps, the diagnosis of endometriosis can take around 10 years, raising the severity of the […]

July 18, 2023 - 9 minutesmins - By Roohi Mariam Peter

News and Trends 18 Jul 2023

Korro Bio and Frequency Therapeutics to merge

Korro Bio, Inc., an RNA editing company focused on the discovery and development of novel genetic medicines, and Frequency Therapeutics, Inc. have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the advancement of Korro Bio’s portfolio of RNA editing programs, is expected to […]

July 18, 2023 - 7 minutesmins - By Jim Cornall

News and Trends 18 Jul 2023

Boost for Charcot-Marie-Tooth patients as Novartis acquires DTx Pharma

DTx Pharma, a preclinical stage biotechnology company addressing the delivery challenges of oligonucleotide therapeutics with its fatty acid ligand conjugated oligonucleotide (FALCON) platform, has been acquired by Novartis. The FALCON platform enables the delivery and activity of small interfering RNA (siRNA) therapeutics to tissues beyond the liver, enhancing biodistribution and cellular uptake. DTx Pharma’s lead […]

July 18, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 18 Jul 2023

FDA approves Beyfortus ahead of 2023-24 RSV season

The U.S. Food and Drug Administration (FDA) has approved Sanofi and AstraZeneca’s Beyfortus (nirsevimab-alip) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season. The approval also covers children up to 24 months of age who remain vulnerable to severe […]

July 18, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 17 Jul 2023

Hope for Alzheimer’s patients after Lilly drug results

Eli Lilly and Company has presented full results from its phase 3 TRAILBLAZER-ALZ 2 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease (AD). The data were shared at the 2023 Alzheimer’s Association International Conference (AAIC) as a featured symposium and simultaneously published in the Journal of […]

July 17, 2023 - 6 minutesmins - By Jim Cornall

News and Trends 17 Jul 2023

Westlake launches $450M fund for LA biotechs

Westlake Village BioPartners has launched its third fund of $450 million to incubate and grow early stage next-generation biotechnology companies in the Los Angeles region and beyond. The new fund will be managed by founding managing director Beth Seidenberg, managing director Mira Chaurushiya, and David Allison, who was recently appointed managing director. “This new fund […]

July 17, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 17 Jul 2023

Lilly boosts obesity portfolio with Versanis Bio acquisition

Eli Lilly and Company is set to acquire Versanis Bio in a deal that could be worth close to $2 billion. Versanis Bio is a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases. Versanis’ lead asset is bimagrumab, a monoclonal antibody that binds activin type II […]

July 17, 2023 - 2 minutesmins - By Jim Cornall

Best in Biotech 14 Jul 2023

Six radiopharmaceutical companies making a difference

Radiopharmaceuticals are a kind of pharmaceutical drug that contain radioisotopes that bind to biological molecules in order to target specific cells and tissues. A pioneer in the field of precision medicine, a growing body of research suggests that this class of medicine could deliver radiotherapy with enhanced specificity to cancer cells. With a market value […]

July 14, 2023 - 6 minutesmins - By Roohi Mariam Peter

Podcast 14 Jul 2023

Beyond Biotech podcast 54

1:24 Labiotech news3:45 TolerogenixX This week, we have a conversation with Matthias Schaier, CEO of TolerogenixX, about tackling rejection of organs following transplantation. TolerogenixX GmbH, a biopharmaceutical company developing personalized cellular therapies aimed at achieving sustained immune tolerance to combat organ rejection and autoimmune diseases, has announced that its phase IIb study in renal transplant […]

July 14, 2023

News and Trends 14 Jul 2023

Life saved: AI discovers existing drug works for rare disease

A patient’s life was saved after researchers at the University of Pennsylvania, Castleman Disease Collaborative Network, Medidata, and Every Cure, used artificial intelligence to use an existing drug to treat idiopathic multicentric Castleman disease (iMCD). Every Cure and its partners are developing medical databases and AI algorithms to unlock new uses for existing medicines across […]

July 14, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 14 Jul 2023

TME Pharma provides positive glioblastoma trial results

TME Pharma N.V. has announced a positive clinical update on the best response to therapy, reporting one patient achieving complete response in the GLORIA expansion arm evaluating NOX-A12, TME Pharma’s CXCL12 inhibitor, in combination with standard of care radiotherapy and anti-VEGF, bevacizumab, in first-line glioblastoma. TME Pharma is a biotechnology company focused on developing novel […]

July 14, 2023 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Moleculin issues acute myeloid leukemia drug data

Ten years to ten days: French startup revolutionizes early diagnosis of endometriosis with a saliva test

Korro Bio and Frequency Therapeutics to merge

Boost for Charcot-Marie-Tooth patients as Novartis acquires DTx Pharma

FDA approves Beyfortus ahead of 2023-24 RSV season

Hope for Alzheimer’s patients after Lilly drug results

Westlake launches $450M fund for LA biotechs

Lilly boosts obesity portfolio with Versanis Bio acquisition

Six radiopharmaceutical companies making a difference

Beyond Biotech podcast 54

Life saved: AI discovers existing drug works for rare disease

TME Pharma provides positive glioblastoma trial results

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!